Case reports

Death due to intravenous use of α-pyrrolidinopentiophenone

Intoxication with synthetic cathinones (psychoactive designer drugs) can involve cardiovascular, autonomic, neuromuscular and neuropsychiatric features. We report a case of cardiac arrest and subsequent death in a 44-year-old man after intravenous use of one such drug — α-pyrrolidinopentiophenone. We believe this is the first death associated with this drug to be reported in Australia. Currently, no specific antidote exists for cathinone exposure.

Clinical record

A 44-year-old man with a history of substance misuse injected himself with a powder named “Smokin’ Slurry Scrubba” that he and his girlfriend had purchased over the counter from a shop. Soon after injecting the powder, the man stripped off all his clothes, jumped over a barbed-wire fence and smashed a window. He was restrained and pinned to the floor by security staff while emergency services were called, during which time he suffered a cardiac arrest.

Cardiopulmonary resuscitation (CPR) was commenced by bystanders. On arrival of ambulance paramedics, the patient was confirmed to be in asystolic cardiac arrest and the paramedics continued CPR. Spontaneous circulation was restored after a further 3 minutes of advanced cardiac life support protocol. He was intubated at the scene by the paramedics. The total duration of cardiac arrest was estimated to be 16 minutes. His vital signs immediately after the arrest were: Glasgow Coma Scale (GCS) score, 3; blood pressure, 65/20 mmHg; heart rate, 85 beats/min; tympanic temperature, 39.7°C. An adrenaline infusion was started at 30 μg/min to treat persistent systemic hypotension.

On arrival at the emergency department, about 1 hour after the cardiac arrest, the patient’s temperature had climbed to 39.9°C and he was still hypotensive (blood pressure, 83/45 mmHg). On physical examination, he had a GCS score of 3, and his pupils were dilated (right, 5 mm; left, 6 mm) and unreactive to light. A venous blood gas and serum analysis using samples taken on arrival at the emergency department showed a severe metabolic and respiratory acidosis with evidence of hyperkalaemia, rhabdomyolysis, ischaemic hepatitis, elevated lactate level and acute renal failure (Box 1). An echocardiogram taken at this time was normal. Results of a qualitative urine drug screen (Roche Diagnostics immunoassay) using a sample taken on the patient’s arrival at the intensive care unit were positive for benzodiazepines but negative for amphetamines, cannabis, cocaine and opioids. There was also evidence of disseminated intravascular coagulation — an international normalised ratio of 2.5 (reference interval [RI], 0.8–1.1), an activated partial thromboplastin time of 82.2 s (RI, 25.0–37.0 s) and a plasma fibrinogen level of 1.4 g/L (RI, 2.20–4.30 g/L) — but no clinical evidence of bleeding. Due to the increasing creatine kinase levels, the patient was started on continuous venovenous haemodiafiltration in an attempt to mitigate further renal damage.

About 24 hours after the cardiac arrest, the patient developed signs of raised intracranial pressure with fixed dilated pupils and haemodynamic instability; he did not respond to noxious stimuli and he had lost brain stem reflexes. A non-contrast computed tomography scan of his brain showed diffuse cerebral oedema with tonsillar herniation and multiple areas of cerebral infarction (Box 2). About 43 hours after the cardiac arrest, the patient was declared brain dead by clinical criteria, and supportive care was withdrawn.

The only physical findings of note on postmortem examination were cerebellar tonsillar herniation and pulmonary oedema. There was no evidence of trauma. Coronial analysis of antemortem and postmortem blood samples (using liquid chromatography mass spectrophotometry) revealed the qualitative presence of α-pyrrolidinopentiophenone (α-PVP). No other common drugs of misuse were detected.

doi:10.5694/mja13.00203
1 Results of a venous blood gas analysis for a 44-year-old man after he had a cardiac arrest due to α-pyrrolidinopentiophenone toxicity

<table>
<thead>
<tr>
<th>Component</th>
<th>1h after arrest</th>
<th>6h after arrest</th>
<th>Reference interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>6.62</td>
<td>7.21</td>
<td>7.35–7.43</td>
</tr>
<tr>
<td>Partial pressure of carbon dioxide (mmHg)</td>
<td>90</td>
<td>42</td>
<td>32–45</td>
</tr>
<tr>
<td>Bicarbonate (mmol/L)</td>
<td>8.8</td>
<td>16.1</td>
<td>22–32</td>
</tr>
<tr>
<td>Lactate (mmol/L)</td>
<td>29.0</td>
<td>4.9</td>
<td>&lt; 2.0</td>
</tr>
<tr>
<td>Potassium (mmol/L)</td>
<td>6.2</td>
<td>3.3</td>
<td>3.6–5.1</td>
</tr>
<tr>
<td>Urea (mmol/L)</td>
<td>13.4</td>
<td>12.4</td>
<td>2.9–7.1</td>
</tr>
<tr>
<td>Creatinine (μmol/L)</td>
<td>201</td>
<td>169</td>
<td>60–110</td>
</tr>
<tr>
<td>Alanine transaminase (U/L)</td>
<td>1976</td>
<td>1913</td>
<td>&lt; 45</td>
</tr>
<tr>
<td>Aspartate transaminase (U/L)</td>
<td>1818</td>
<td>2457</td>
<td>&lt; 45</td>
</tr>
<tr>
<td>Creatine kinase (U/L)</td>
<td>2763</td>
<td>24660</td>
<td>&lt; 200</td>
</tr>
<tr>
<td>Myoglobin (μg/L)</td>
<td>—</td>
<td>43190</td>
<td>10–92</td>
</tr>
</tbody>
</table>

2 Non-contrast computed tomography scans of the brain of a 44-year-old man after he had a cardiac arrest due to α-pyrrolidinopentiophenone toxicity

The formal conclusion of a subsequent coronial inquest was that the patient had died from cardiac arrest and cerebral oedema, which were the results of α-PVP toxicity. The possibility of physical restraint and positional asphyxia contributing to his death was raised but these factors were considered not to be the primary cause of death.

Discussion

To our knowledge, this is the first death due to α-PVP use reported in Australia. Assessing all the evidence, our patient died from the expected complications of exposure to α-PVP.

α-PVP is a synthetic cathinone designer drug that is misused for its stimulant and psychoactive effects. It is an analogue of pyrovalerone (α-PVP) such as 3,4-methylenedioxypyrovalerone (MDPV). Synthetic cathinones such as α-PVP are widely sold on the internet; they are commonly referred to as “bath salts”, “legal highs” or “research chemicals”, and often labelled “not for human consumption” in an effort to evade regulatory control. Synthetic cathinones are also structural analogues of cathinone, the naturally occurring β-ketone amphetamine analogue found in the Catha edulis (Khat) plant.

As structural analogues of β-ketone amphetamines, cathinones are expected to have amphetamine-like effects. Many cathinones have been shown to be inhibitors of monoamine transporters, but selectivity of cathinones for serotonin, noradrenaline and dopamine transporters varies considerably in vitro. Pyrovalerone-cathinones (eg, MDPV) are potent and selective dopamine and noradrenaline uptake blockers, but are not effective releasers of monoamines. The potency of these drugs on the noradrenaline and dopamine transporters is associated with their stimulant and psychoactive effects.

Synthetic cathinones are most commonly nasally instilled (snorted) or ingested, but rectal insertion, inhalation, and intravenous and intramuscular injection have also been described. Desirable effects of cathinones reported by users include increases in energy, empathy and libido.

The effects of synthetic cathinones (as a group) are said to begin to occur within 15–45 minutes of exposure and the desired effects last from 2 to 7 hours. However, the undesirable effects can last from hours to days. Clinical features of synthetic cathinone intoxication include cardiovascular, autonomic, neuromuscular and neuropsychiatric symptoms and signs (Box 3).

No specific antidote exists for cathinone exposure, and there are limited published data on specific management strategies. Current practice is based on experience treating patients intoxicated with other sympathomimetic drugs, for which supportive care is the mainstay of treatment. Benzodiazepines are recommended for control of agitation and seizures, and for treatment of hypertension and tachycardia, and passive or active cooling is recommended for treatment of hyperthermia that is not resolved with anxiolysis and sedation. In Australia, poisons information centres can be contacted for further advice.

While there have been a few media reports of violence, aggression and deaths related to use of α-PVP, few cases have been reported in peer-reviewed journals. One article describes the deaths of five patients for whom α-PVP was detected in postmortem blood, but this does not necessarily mean that α-PVP intoxication was the cause of death or that α-PVP was the only drug present. Another article describes a case of parenteral MDPV overdose, confirmed by a quantitative assay of MDPV in the patient’s blood, in which the clinical course was very similar to that of our patient.

Our patient probably died as a consequence of the complications of α-PVP exposure. The time of death and
clinical course fit with the features of autonomic hyper-arousal: psychomotor agitation, delirium, tachycardia and hyperthermia, and subsequent cardiac arrest, rhabdomyolysis, renal failure, hepatic injury, anoxic brain injury and death. These features have also been described as “excited delirium syndrome”.8 Excited delirium syndrome as a diagnostic entity is controversial and widely debated in the medical literature. The role of excessive stimulation of the sympathetic nervous system in subsequent cardiac death after drug exposure has also been widely debated. It has been postulated that overstimulation of the heart by catecholamines leads to increased contractility, blood pressure and heart rate, resulting in increased oxygen demand, followed by myocardial ischaemia, fatal cardiac arrhythmias and sudden death.

The single biggest factor influencing death from α-PVP intoxication as the outcome in this case was the route of exposure to the drug — that is, intravenous injection. From toxicokinetic first principles, this results in faster and higher blood concentrations of drugs compared with ingestion and nasal insufflation as routes of exposure.

Synthetic cathinones have been present in notable quantities in Australia since the mid 2000s. While the exact prevalence of use in Australia is difficult to determine, the availability and popularity of synthetic cathinones has increased over the past decade, as evidenced by surveys of regular drug users, wastewater analyses and drug seizures by the Australian Federal Police.9

Our patient tested negative for amphetamines when a urine drug screen was performed. Testing for α-PVP was only available through coronial investigation. This highlights that medical professionals in Australia need to be aware of the limitations of commonly available drug screens, which might not detect new psychoactive substances.

Competing interests: No relevant disclosures.

Received 10 Dec 2013, accepted 14 Mar 2014.